Research Article
Study of Paraoxonase1 Enzyme for Women with Breast Cancer (Biochemical and Molecular Genetics Study)
Abstract
The
research include studying biochemical and genetic molecular study for
paraoxonase1 enzyme and identify some biochemical parameters for serum blood
samples 68 women with breast cancer and follow-up after take them three doses
of chemotherapy and comparative with 50 normal female as control group.The
result showed for women with breast cancer a significant increase in (TC,MDA
,Total protein, U,A , calcium and BMI) when compared with normal women, the
results also showed for women who have taken chemical doses and women with
breast cancer significant decreased in (PON1, GSH) compared with normal women,
the results showed for women who have taken
the first dose significant increase in (MDA,TP, Calcium, U.A , BMI),
while second dose and the third dose chemotherapy found significant increase in
(TP, U.A ,Calcium ) and significant decreased for (PON1). The results included
sequential analysis for PON1 enzyme ,it has shown results for genetic analyzed
selected exon (Exon4), where DNA extraction for normal women and breast cancer
women and taken their doses of chemotherapy and measure DNA concentration and
purity using Nano-Drop Spectrophotometric Analysis where the result show the
DNA concentration ranged between (5.2-68.4) ng/ml where concentration mean for
women with breast cancer (26.97) ng/ml and (17.49) ng/ml for normal women while
the first dose 24.74 ng/ml , (16.16-9.70)ng/ml for second and third dose
respectively . It has also been used PCR technique amplification and test products PCR analysis of sequential
technique by using gel electrophoresis where packet appeared clear without
deformation and tested PCR product sequencing for exon4 by capillary automated
sequencer and comparing the result with the normal sequence of the oxon.,
the results shows for women have taken first dose deletion mutation called
(Remove) frame shift mutation clear nitrogen base one lead to change all codons
after deletion site so that all amino acid change in poly protien chain which
led to the loss of amino acid (Tyr.) . and mutation type of silent mutation third mutation type of
substitution mutation (Replace amino acid (Thr.) by amino acid (Ser.).
Keywords
References
- Abdel-Salam O., Youness E., Hafez H.,(2011)” The antioxidant status of the plasma in patients with breast cancer undergoing chemotherapy”Open Journal of Molecular and Integrative Physiology,1:pp:29-35. Abu-Bedair F.A.,El-Gamal B. A. ,Ibrahim N.A., El-Aaser A.A.,(2003) “ Serum lipids and tissue DNA content in egyptian female breast cancer patients “ Jpn. J. Clin. Oncol. ,33(6) ,278-282. Agachan B, Yilmaz H, Karaali Z, Isbir T.(2004)” Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus” Cell Biochem Funct ,22 : 163-8. Aghvami T., Djalali M.,Keshavarz A., Sadeghi M.R.,Zeruati H.,Yeganeh H.H., Negahdar M., (2006) “ Plasma level of antioxidant vitamins and lipid peroxidation in breast cancer patients “ Iranian J. Pubi. Health , 35(1),pp.42-47. Aksoy-Sagirli P, Cakmakoglu B, Isbir T, Kaytan SE, Kizir A, Topuz E, et al.(2011)” Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population” Anti cancer Res, 31(6): 2225–9. Ali, A.B., Zhang, Q., Lim, Y.K., Fang, D., Retnam, L., (2003)”Expression of major HDL associated antioxidant PON-1 is gender and regulated during inflammation” Free Rad Bio & Med, 34, 824-829. Almquist M., Anagnostaki l.,Bondeson L. , Berrgguist S., Landberg G., Malina J., Manjer J., (2009) “ Serum calcium and tumour aggressiveness in breast cancer: a prospective study of women” Eur. J. Cancer Prev.;18(5) :354-360. Alwan N., Al Attar W, Eliessa R, Al-Madfaie Z and Nedal,F.,(2012)” Knowledge and practices of women in Iraqi universities on breast self examination” Eastern Mediterranean Health Journal, Vol.18, Issue.7,pp: -742-748 American cancer Society (the History of cancer )1-800-227-2345 (2014) www.bordet ,be/en/presentation /history / cancer / cancer1 , htm. American Cancer Society 2015( Body weight and cancer risk) ,31-800-227-2345. American cancer Society(2014)“Kideny cancer (Adult)-Renal cell carcinoma” www.bordet ,be/en/presentation// Renal cell carcinoma Ames B.N., Cathcart R., Sehwiers E., Hochstein P., (1981) “ Uric acid provides an antioxidant defense in humans against oxidant –and radical –caused aging and cancer : a hypothesis “ Proc. Natl. Acad. Sci . USA;78(11) :6858-6862. Arpaci A, Gormus U, Dalan B, Berkman S, Isbir T. (2009)”Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population” In Vivo, 23(3):421–4. Askar T.K., Buyukkebletici O., (2012) ”Paraoxonase : Anew biochemical marker of oxidant –Antioxidant status in atherosclerosis” ,Oxidative stress,145-154 Aviram, M., Rosenblat, M.,(2004)”Paraoxonases1,2 and 3,oxidative stress, and macrophage foam cell formation during atherosclerosis development” Free Radical Biology &Medicine,37,304–1316 Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Nacak M, Tapanyigit EE, Roots I.(1999)” Paraoxonase 1 mutations in a Turkish population”Toxicol Appl Pharmacol,157(3): 174–7. Bayrak, T., Bayrak, A., Demirpençe, E., Kılınç, K., (2005)”Yeni bir kardiyovasküler belirteç adayı: Paraoxonaz,” Hacettepe Medical Journal, 36,147-151. Benhar M.,Engelberg D., Levitzki A., (2002) “ Roes, Stress-activated kinases and Stress Sig naling in cancer "EMBO reports Berclaz G., Li S., Price K.N.,Coates A.S., Castiglione-Gertsch M., Rudenstam C. -M.,Holmberg S.B.,Lindtner J., Erzen D., Collins J.,etal.,(2004)” Body mass index as a prognostic feature in operable breast cancer: the international breast cancer study group experience “Annals of Oncology , 15:875-884. Blecher E., Chaney-Graves K. , Desantis C., Edward B. . Ferlay J. , Forman D., Grey N., Harford J., Kramer J.,Mc Mikel A., etc., (2011) “Global cancer Facts and food”2nd ed,American cancer society, pp:1-55 Coombes R.C., Powles T.J., and Joptin G.F.,(1977)”Calcium metabolism in breast cancer “ Proc. Roy. Soc. Med.,Vol.70,pp195-199. Costa, LG., Vitalone, A., Cole, TB., Furlong, CE.(2005)”Modulation of paraoxonase (PON1) activity”Biochemical Pharmacology, 69: 541-550. Coughlin S., and Cypel Y., (2013) “ Epidemiology of breast cancer in women ” Chapter 2 Springer Science Business Media New York , pp.13-34. Dai-Hua F, Cong-Hai F, Qiang J, Bo-Xiang Q, Juan L, Lu W. (2012)”Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies” Molecular Biology Reports, 39:6801–9. Das U.,(2002) ”A radical approach to cancer " Med. Sci. Monit., 8(4) : RA79-RA92 Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE.(1996)”The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin” Nat Genet ,14 : 334-6. Durrington P.O., Mackness B., Mackness M.L.(2001) “ Paraoxonase and atheresclerosis” arteriosclerosis , thrombosis and vascular biology;21:473-480 Elkiran E., Mar N. , Aygen B., Gursu F.,Karuoglu A., and Koca S., (2007) “ Serum paraoxonase and arylesterase activities in patients with lung cancer in turkish population “ Bio. Med. Cancer, pp1-8. Escribano B., Moreno A., Tasset I., Tunez I.,(2014)” Impact of light /dark cycle patterns on oxidative stress in an Adriamycin-induced nephropathy model in rats “ Plos one,Vol.9,Issue.5,pp.1-10. Fairbanks V, Klee GG, (1986).”Biochemical aspects of hematology. In: N.W. Tietz Editor” Textbook of clinical chemistry W.B. Saunders, Philadelphia. 1532–1534. Fatima T., (2013) “ Circulatory proteins in women with breast cancer and their chemotherapeutic responses” Pakistan J. Zool., Vol.45, pp: 1207 -1213. Fini M.A., Elias A., Johnson R.,and Wright R.,(2012) “ Contribution of uric acid to cancer risk , recurrence , and mortality “ Clinical and Translational Medicine J. ; 1 : 16 (http://www.clintransmed.Com/ content / 1 /1/16. Florea A., Busselberg D., (2009) “ Anti-cancer drugs interfere with intracellular calcium signaling “ Neurotoxicology .,30,803-810. Furiong C., Richter R., Chapline C., and Crabb J., (1991) ” Purification of rabbit and human serum paraoxonase “ Biochemistry ,30,10133-10140 Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, et al.(2007) ”Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease” Cancer Detect Prev 2007; 31(2): 95–101. Gouedard C.,Koum-Besson N.,Barouki R., Moral Y.,(2003)”Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins” Molecular Pharmacology ,Vol.63, pp.945-956. Gutowski M., and Kowalczyk S., (2013) ”Astudy of free radical chemistry :their role and pathophysiological significance “ACTA Biochemical polonical ,Vol.60,No.1, pp1-16. Guyton A.C., and Hall j.E.,(2001)“ Texbook of medical physiology ” 11th ed.,Elsvier.,Sauuders com .,philndelphia, pp.46-47. Han, X., Shen, T., Lou, H. (2007)”Dietary Polyphenols and Their Biological Significance” Int J Mol Sci. ,8: 950-988. Hejmadi M. (2010) “introduction to cancer biology ”2nd ed.,Momna Hejmadi & bookboon.com, pp.7,22,11,36,66. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE.(1993)”The molecular basis of the human serum paraoxonase activity polymorphism”Nat Genet ,3 : 73-6. Inal V., Yamanel L., Taskin G., Tanpan S., Comert B., (2015) ”Paraoxonase1 activity and survival in sepsis patients “ Balkan Med J.,32:PP183-188. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC.(2000)” Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients” Diabetes ,49 : 1390-3. Junior A.L.G.,Paz M., De silva L., Carvalho S., Sobral A., Machado K., Ferreira P., Satyal P., (2015) “ Serum oxidative stree markers and genotoxic profile induced by chemotherapy in patients with breast cancer : A Pilotstudy “ Hindavi Pubishing Corporation ,1-18. Liaveras G.,Danilo C.,Mercier I.,Daumer K.,Capozza F.,Williams T.M.,Sotgia F.,Lisanti M.P.,and Frank P.G.,(2011)”Role of cholesterol in the development and progression of breast cancer “American Journal of Patbology ,Vol.178,No.1 ,pp402-421 Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT, (2008)”Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma” Cancer Epidemiol Biomarkers Prev,17(8): 2070–7. Moren X, Deakin S, Liu ML, Taskinen MR, James RW.(2008)”HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress” J Lipid Res.49 :1246-53. Nakayamma A., Alladin K., Lgbokw C., White J., (2011) “ Systematic review : generating evidence based guide lines on the concurrent use of dietary antioxidant and chemotherapy or radiotherapy “ Cancer Invest.; 29(10) : 655-667. Nicholas,T.,(2013)“Cancer ”Hindwi foundation for education and culture pp.17,17,18,47 Noori S., (2012) “ On overview of Oxidative stress and antioxidant defense system “Citation Open Access,Nooti;1-8 ,1:413-,109 Nourazarian A., Kangari P., Salmanineejad A., (2014) “ Roles of oxidative stress in the development and progression of breast cancer “ Asian Pacific Journal of Cancer , Vol.15,4745-4751. Pan Z.,Avila A., Gollahon L.,(2014)” Paclitaxel induced apoptosis in breast cancer cells through different calcium –regulating mechanisms depending on external calcium conditions”Int. J. Mol. Sci.Vol.15,2672-2694. Rinaldi C., Anglo R., Ruggeri A., Calabro M., Scimone C., and Sidoti A.,(2014) ” PON1 gene polymorphisms Cancer :A case –control study in apopulation from sothern italy “ J. Mol. Biomarker and Diagnosis ,5: ISSNE.2 ;2-6. Rzymowska J., (2011) “ Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients “ Pathobiology ;67,: 129-132. Searles Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H. (2005)” Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1)” Environ Health Perspect,113(7): 909–13. Sharma N., Rai M.,(2014)” Lipid peroxidation status in different stages of breast cancer women treated by chemotherapy”European Academic Research,Vol.11,Issue.4,pp.5661-5668. Sheeh A.,(2010) “Comparative study of renoprotective effects of captopril and aminophylline against cisplatine induced nephrotoxicity in rats “ Al-Kindy College. Med. J. 6 , (1),pp:1-12. Singh M., and Jangra, B.,(2013) “Association between body mas index and Risk of Breast cancer among femaler of north India ”South Asia J. Cancer ,2(3):121-125 Sokal R.R. and Rohlf F.J.,(2012)”Biometry : the principles and practice of statistics in biological research “ 4th ed. W.H.Freeman and Co.newyork.937pp. Soliman H., Ahmed R., Gomaa H., Ali A.,(2014)”Assessment of the chemo-preventive effects if variouse plant constituents against doxorubicin-induced toxicity in rats”J. of American Science ;10(9):153-164. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN.(1999)” Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity” Arterioscler Thromb Vasc Biol,19 : 2214-25. Suga S., and Tamura Z., (1972) “ Analysis of serum protein changes in patients with special reference to x-globulin fractions “ Cancer Research ,32,426-429. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J. (2012)” Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk” Arterio scler Thromb Vasc Biol , 32(11):2803–12. Uchiyama M, Mihara M, (1978)”Determination of malonaldehyde precursor in tissues by thiobarbituric acid test” Anal. Biochem.,34:271-278. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. (2007)”Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects” Eur J Clin Invest,37 :715-23. Vidhye R., Jayanthi M., Kanagavalli U.,(2010) “ Protective effect of captoxrll against cisplatine in auced nephrotoxicity in rats “ Pharmacology online.,1:12-15. Yadav N.K.,Poudel B.,Thanpari C., Koner B., (2012) “ Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer “ Asian Pacific J. Cancer Prev., Vol.13, pp.3385-3388. Yildirim S., Kisa F., KLarddeniz A.,Yildirim A., Karakor A., Can I., Kara A., Simsek N.M.,(2012)“effects of pomegranate seed extract on liver paraoxonase and bcI-XLactivites in rats treated with cisplatin” Journal of Medicinal Plants Research ,Vol.6(12),pp.2317-2323. Yılmaz N.(2012)” Relationship between paraoxonase and homocysteine: crossroads of oxidative disease” Arch Med Sci ,8(1): 138–53.
Year 2018,
Issue: 3, 56 - 71, 01.12.2018
Abstract
References
- Abdel-Salam O., Youness E., Hafez H.,(2011)” The antioxidant status of the plasma in patients with breast cancer undergoing chemotherapy”Open Journal of Molecular and Integrative Physiology,1:pp:29-35. Abu-Bedair F.A.,El-Gamal B. A. ,Ibrahim N.A., El-Aaser A.A.,(2003) “ Serum lipids and tissue DNA content in egyptian female breast cancer patients “ Jpn. J. Clin. Oncol. ,33(6) ,278-282. Agachan B, Yilmaz H, Karaali Z, Isbir T.(2004)” Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus” Cell Biochem Funct ,22 : 163-8. Aghvami T., Djalali M.,Keshavarz A., Sadeghi M.R.,Zeruati H.,Yeganeh H.H., Negahdar M., (2006) “ Plasma level of antioxidant vitamins and lipid peroxidation in breast cancer patients “ Iranian J. Pubi. Health , 35(1),pp.42-47. Aksoy-Sagirli P, Cakmakoglu B, Isbir T, Kaytan SE, Kizir A, Topuz E, et al.(2011)” Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population” Anti cancer Res, 31(6): 2225–9. Ali, A.B., Zhang, Q., Lim, Y.K., Fang, D., Retnam, L., (2003)”Expression of major HDL associated antioxidant PON-1 is gender and regulated during inflammation” Free Rad Bio & Med, 34, 824-829. Almquist M., Anagnostaki l.,Bondeson L. , Berrgguist S., Landberg G., Malina J., Manjer J., (2009) “ Serum calcium and tumour aggressiveness in breast cancer: a prospective study of women” Eur. J. Cancer Prev.;18(5) :354-360. Alwan N., Al Attar W, Eliessa R, Al-Madfaie Z and Nedal,F.,(2012)” Knowledge and practices of women in Iraqi universities on breast self examination” Eastern Mediterranean Health Journal, Vol.18, Issue.7,pp: -742-748 American cancer Society (the History of cancer )1-800-227-2345 (2014) www.bordet ,be/en/presentation /history / cancer / cancer1 , htm. American Cancer Society 2015( Body weight and cancer risk) ,31-800-227-2345. American cancer Society(2014)“Kideny cancer (Adult)-Renal cell carcinoma” www.bordet ,be/en/presentation// Renal cell carcinoma Ames B.N., Cathcart R., Sehwiers E., Hochstein P., (1981) “ Uric acid provides an antioxidant defense in humans against oxidant –and radical –caused aging and cancer : a hypothesis “ Proc. Natl. Acad. Sci . USA;78(11) :6858-6862. Arpaci A, Gormus U, Dalan B, Berkman S, Isbir T. (2009)”Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population” In Vivo, 23(3):421–4. Askar T.K., Buyukkebletici O., (2012) ”Paraoxonase : Anew biochemical marker of oxidant –Antioxidant status in atherosclerosis” ,Oxidative stress,145-154 Aviram, M., Rosenblat, M.,(2004)”Paraoxonases1,2 and 3,oxidative stress, and macrophage foam cell formation during atherosclerosis development” Free Radical Biology &Medicine,37,304–1316 Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Nacak M, Tapanyigit EE, Roots I.(1999)” Paraoxonase 1 mutations in a Turkish population”Toxicol Appl Pharmacol,157(3): 174–7. Bayrak, T., Bayrak, A., Demirpençe, E., Kılınç, K., (2005)”Yeni bir kardiyovasküler belirteç adayı: Paraoxonaz,” Hacettepe Medical Journal, 36,147-151. Benhar M.,Engelberg D., Levitzki A., (2002) “ Roes, Stress-activated kinases and Stress Sig naling in cancer "EMBO reports Berclaz G., Li S., Price K.N.,Coates A.S., Castiglione-Gertsch M., Rudenstam C. -M.,Holmberg S.B.,Lindtner J., Erzen D., Collins J.,etal.,(2004)” Body mass index as a prognostic feature in operable breast cancer: the international breast cancer study group experience “Annals of Oncology , 15:875-884. Blecher E., Chaney-Graves K. , Desantis C., Edward B. . Ferlay J. , Forman D., Grey N., Harford J., Kramer J.,Mc Mikel A., etc., (2011) “Global cancer Facts and food”2nd ed,American cancer society, pp:1-55 Coombes R.C., Powles T.J., and Joptin G.F.,(1977)”Calcium metabolism in breast cancer “ Proc. Roy. Soc. Med.,Vol.70,pp195-199. Costa, LG., Vitalone, A., Cole, TB., Furlong, CE.(2005)”Modulation of paraoxonase (PON1) activity”Biochemical Pharmacology, 69: 541-550. Coughlin S., and Cypel Y., (2013) “ Epidemiology of breast cancer in women ” Chapter 2 Springer Science Business Media New York , pp.13-34. Dai-Hua F, Cong-Hai F, Qiang J, Bo-Xiang Q, Juan L, Lu W. (2012)”Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies” Molecular Biology Reports, 39:6801–9. Das U.,(2002) ”A radical approach to cancer " Med. Sci. Monit., 8(4) : RA79-RA92 Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE.(1996)”The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin” Nat Genet ,14 : 334-6. Durrington P.O., Mackness B., Mackness M.L.(2001) “ Paraoxonase and atheresclerosis” arteriosclerosis , thrombosis and vascular biology;21:473-480 Elkiran E., Mar N. , Aygen B., Gursu F.,Karuoglu A., and Koca S., (2007) “ Serum paraoxonase and arylesterase activities in patients with lung cancer in turkish population “ Bio. Med. Cancer, pp1-8. Escribano B., Moreno A., Tasset I., Tunez I.,(2014)” Impact of light /dark cycle patterns on oxidative stress in an Adriamycin-induced nephropathy model in rats “ Plos one,Vol.9,Issue.5,pp.1-10. Fairbanks V, Klee GG, (1986).”Biochemical aspects of hematology. In: N.W. Tietz Editor” Textbook of clinical chemistry W.B. Saunders, Philadelphia. 1532–1534. Fatima T., (2013) “ Circulatory proteins in women with breast cancer and their chemotherapeutic responses” Pakistan J. Zool., Vol.45, pp: 1207 -1213. Fini M.A., Elias A., Johnson R.,and Wright R.,(2012) “ Contribution of uric acid to cancer risk , recurrence , and mortality “ Clinical and Translational Medicine J. ; 1 : 16 (http://www.clintransmed.Com/ content / 1 /1/16. Florea A., Busselberg D., (2009) “ Anti-cancer drugs interfere with intracellular calcium signaling “ Neurotoxicology .,30,803-810. Furiong C., Richter R., Chapline C., and Crabb J., (1991) ” Purification of rabbit and human serum paraoxonase “ Biochemistry ,30,10133-10140 Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, et al.(2007) ”Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease” Cancer Detect Prev 2007; 31(2): 95–101. Gouedard C.,Koum-Besson N.,Barouki R., Moral Y.,(2003)”Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins” Molecular Pharmacology ,Vol.63, pp.945-956. Gutowski M., and Kowalczyk S., (2013) ”Astudy of free radical chemistry :their role and pathophysiological significance “ACTA Biochemical polonical ,Vol.60,No.1, pp1-16. Guyton A.C., and Hall j.E.,(2001)“ Texbook of medical physiology ” 11th ed.,Elsvier.,Sauuders com .,philndelphia, pp.46-47. Han, X., Shen, T., Lou, H. (2007)”Dietary Polyphenols and Their Biological Significance” Int J Mol Sci. ,8: 950-988. Hejmadi M. (2010) “introduction to cancer biology ”2nd ed.,Momna Hejmadi & bookboon.com, pp.7,22,11,36,66. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE.(1993)”The molecular basis of the human serum paraoxonase activity polymorphism”Nat Genet ,3 : 73-6. Inal V., Yamanel L., Taskin G., Tanpan S., Comert B., (2015) ”Paraoxonase1 activity and survival in sepsis patients “ Balkan Med J.,32:PP183-188. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC.(2000)” Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients” Diabetes ,49 : 1390-3. Junior A.L.G.,Paz M., De silva L., Carvalho S., Sobral A., Machado K., Ferreira P., Satyal P., (2015) “ Serum oxidative stree markers and genotoxic profile induced by chemotherapy in patients with breast cancer : A Pilotstudy “ Hindavi Pubishing Corporation ,1-18. Liaveras G.,Danilo C.,Mercier I.,Daumer K.,Capozza F.,Williams T.M.,Sotgia F.,Lisanti M.P.,and Frank P.G.,(2011)”Role of cholesterol in the development and progression of breast cancer “American Journal of Patbology ,Vol.178,No.1 ,pp402-421 Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT, (2008)”Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma” Cancer Epidemiol Biomarkers Prev,17(8): 2070–7. Moren X, Deakin S, Liu ML, Taskinen MR, James RW.(2008)”HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress” J Lipid Res.49 :1246-53. Nakayamma A., Alladin K., Lgbokw C., White J., (2011) “ Systematic review : generating evidence based guide lines on the concurrent use of dietary antioxidant and chemotherapy or radiotherapy “ Cancer Invest.; 29(10) : 655-667. Nicholas,T.,(2013)“Cancer ”Hindwi foundation for education and culture pp.17,17,18,47 Noori S., (2012) “ On overview of Oxidative stress and antioxidant defense system “Citation Open Access,Nooti;1-8 ,1:413-,109 Nourazarian A., Kangari P., Salmanineejad A., (2014) “ Roles of oxidative stress in the development and progression of breast cancer “ Asian Pacific Journal of Cancer , Vol.15,4745-4751. Pan Z.,Avila A., Gollahon L.,(2014)” Paclitaxel induced apoptosis in breast cancer cells through different calcium –regulating mechanisms depending on external calcium conditions”Int. J. Mol. Sci.Vol.15,2672-2694. Rinaldi C., Anglo R., Ruggeri A., Calabro M., Scimone C., and Sidoti A.,(2014) ” PON1 gene polymorphisms Cancer :A case –control study in apopulation from sothern italy “ J. Mol. Biomarker and Diagnosis ,5: ISSNE.2 ;2-6. Rzymowska J., (2011) “ Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients “ Pathobiology ;67,: 129-132. Searles Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H. (2005)” Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1)” Environ Health Perspect,113(7): 909–13. Sharma N., Rai M.,(2014)” Lipid peroxidation status in different stages of breast cancer women treated by chemotherapy”European Academic Research,Vol.11,Issue.4,pp.5661-5668. Sheeh A.,(2010) “Comparative study of renoprotective effects of captopril and aminophylline against cisplatine induced nephrotoxicity in rats “ Al-Kindy College. Med. J. 6 , (1),pp:1-12. Singh M., and Jangra, B.,(2013) “Association between body mas index and Risk of Breast cancer among femaler of north India ”South Asia J. Cancer ,2(3):121-125 Sokal R.R. and Rohlf F.J.,(2012)”Biometry : the principles and practice of statistics in biological research “ 4th ed. W.H.Freeman and Co.newyork.937pp. Soliman H., Ahmed R., Gomaa H., Ali A.,(2014)”Assessment of the chemo-preventive effects if variouse plant constituents against doxorubicin-induced toxicity in rats”J. of American Science ;10(9):153-164. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN.(1999)” Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity” Arterioscler Thromb Vasc Biol,19 : 2214-25. Suga S., and Tamura Z., (1972) “ Analysis of serum protein changes in patients with special reference to x-globulin fractions “ Cancer Research ,32,426-429. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J. (2012)” Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk” Arterio scler Thromb Vasc Biol , 32(11):2803–12. Uchiyama M, Mihara M, (1978)”Determination of malonaldehyde precursor in tissues by thiobarbituric acid test” Anal. Biochem.,34:271-278. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. (2007)”Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects” Eur J Clin Invest,37 :715-23. Vidhye R., Jayanthi M., Kanagavalli U.,(2010) “ Protective effect of captoxrll against cisplatine in auced nephrotoxicity in rats “ Pharmacology online.,1:12-15. Yadav N.K.,Poudel B.,Thanpari C., Koner B., (2012) “ Assessment of biochemical profiles in premenopausal and postmenopausal women with breast cancer “ Asian Pacific J. Cancer Prev., Vol.13, pp.3385-3388. Yildirim S., Kisa F., KLarddeniz A.,Yildirim A., Karakor A., Can I., Kara A., Simsek N.M.,(2012)“effects of pomegranate seed extract on liver paraoxonase and bcI-XLactivites in rats treated with cisplatin” Journal of Medicinal Plants Research ,Vol.6(12),pp.2317-2323. Yılmaz N.(2012)” Relationship between paraoxonase and homocysteine: crossroads of oxidative disease” Arch Med Sci ,8(1): 138–53.
There are 1 citations in total.
Details
| Primary Language | English |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | December 1, 2018 |
| Published in Issue | Year 2018Issue: 3 |
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.